CD19-redirected chimeric antigen receptor-modified T cells: A promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL)

Therapeutic Advances in Hematology

Volumn 6, Issue 5, 2015, Pages 228-241

  Tasian, Sarah K ^a   Gardner, Rebecca A ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

acute lymphoblastic leukemia; B cell; CD19; chimeric antigen receptor; cytokine release syndrome; immunotherapy; pediatric; T cell

Indexed keywords

B LYMPHOCYTE ANTIGEN; BLINATUMOMAB; CD135 ANTIGEN; CD19 ANTIGEN; CETUXIMAB; CHIMERIC ANTIGEN RECEPTOR; IMMUNOGLOBULIN; RITUXIMAB; TOCILIZUMAB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN BINDING; APLASIA; B CELL LEUKEMIA; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CELL EXPANSION; CELL STIMULATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE SYNDROME; CYTOTOXICITY; DEGRANULATION; EVENT FREE SURVIVAL; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MACROPHAGE ACTIVATION SYNDROME; NONHUMAN; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR LYSIS SYNDROME; TUMOR XENOGRAFT; UBIQUITINATION;

EID: 84993736234     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620715588916     Document Type: Review

References (63)

1. Barrett D. Liu X. Jiang S. June C. Grupp S. Zhao Y. (2013) Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia. Hum Gene Ther 24: 717–727.
2. Barrett D. Teachey D. Grupp S. (2014) Toxicity management for patients receiving novel T-cell engaging therapies. Curr Opin Pediatr 26: 43–49.
3. Barrett D. Zhao Y. Liu X. Jiang S. Carpenito C. Kalos M. et al. (2011) Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum Gene Ther 22: 1575–1586.
4. Bhojwani D. Pui C. (2013) Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol 14: e205–e217.
5. Borowitz M. Devidas M. Hunger S. Bowman W. Carroll A. Carroll W. et al. (2008) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a children's oncology group study. Blood 111: 5477–5485.
6. Brentjens R. Davila M. Riviere I. Park J. Wang X. Cowell L. et al. (2013) CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5: 177-238.
7. Brentjens R. Riviere I. Park J. Davila M. Wang X. Stefanski J. et al. (2011) Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118: 4817–4828.
8. Brentjens R. Santos E. Nikhamin Y. Yeh R. Matsushita M. La Perle K. et al. (2007) Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 13: 5426–5435.
9. Cooper L. Al-Kadhimi Z. Digiusto D. Kalos M. Colcher D. Raubitschek A. et al. (2004) Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies. Blood Cells Mol Dis 33: 83–89.
10. Cramer P. Hallek M. (2012) Hematological cancer in 2011: new therapeutic targets and treatment strategies. Nat Rev Clin Oncol 9: 72–74.
11. Cruz C. Micklethwaite K. Savoldo B. Ramos C. Lam S. Ku S. et al. (2013) Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 122: 2965–2973.
12. Davila M. Brentjens R. Wang X. Riviere I. Sadelain M. (2012) How do CARs work? Early insights from recent clinical studies targeting CD19. Oncoimmunology 1: 1577–1583.
13. Davila M. Riviere I. Wang X. Bartido S. Park J. Curran K. et al. (2014) Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6: 224-225.
14. Fielding A. Richards S. Chopra R. Lazarus H. Litzow M. Buck G. et al. (2007) Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 109: 944–950.
15. Forman S. Rowe J. (2013) The myth of the second remission of acute leukemia in the adult. Blood 121: 1077–1082.
16. Fry T. Mackall C. (2013) T-cell adoptive immunotherapy for acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2013: 348–353.
17. Gardner R. Jensen M. (2014) CD19CAR T cells: from humble beginnings to cancer immunotherapy's poster child. Cancer J 20:107–111.
18. Gardner R. Park J. Kelly-Spratt K. Finney O. Smithers H. Hoglund V. et al. (2014) T cell products of defined CD4:CD8 composition and prescribed levels of CD19CAR/Egfrt transgene expression mediate regression of acute lymphoblastic leukemia in the setting of post allohsct relapse. Blood 124: abstract #3711.
19. Gross G. Waks T. Eshhar Z. (1989) Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A 86: 10024–10028.
20. Grunwald M. Levis M. (2013) FLT 3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance. Int J Hematol 97: 683–694.
21. Grupp S. (2014) Advances in T-cell therapy for all. Best Pract Res Clin Haematol 27: 222–228.
22. Grupp S. Kalos M. Barrett D. Aplenc R. Porter D. Rheingold S. et al. (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368: 1509–1518.
23. Hanahan D. Weinberg R. (2000) The hallmarks of cancer. Cell 100: 57–70.
24. Howard S. Jones D. Pui C. (2011) The tumor lysis syndrome. N Engl J Med 364: 1844–1854.
25. Inaba H. Greaves M. Mullighan C. (2013) Acute lymphoblastic leukaemia. Lancet 381: 1943–1955.
26. Jeha S. Pui C. (2009) Risk-adapted treatment of pediatric acute lymphoblastic leukemia. Hematol Oncol Clin North Am 23: 973–990.
27. Jena B. Moyes J. Huls H. Cooper L. (2014) Driving CAR-based T-cell therapy to success. Curr Hematol Malig Rep 9: 50–56.
28. Jensen M. Popplewell L. Cooper L. Digiusto D. Kalos M. Ostberg J. et al. (2010) Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant 16: 1245–1256.
29. Kalos M. Levine B. Porter D. Katz S. Grupp S. Bagg A. et al. (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3: 95-173.
30. Kebriaei P. Huls H. Singh H. Olivares S. Figliola M. Kumar P. et al. (2013) First clinical trials employing sleeping beauty gene transfer system and artificial antigen presenting cells to generate and infuse T cells expressing CD19-specific chimeric antigen receptor. Blood 123: abstract #166.
31. Kebriaei P. Huls H. Singh H. Olivares S. Figliola M. Maiti S. et al. (2014) Adoptive therapy using sleeping beauty gene transfer system and artificial antigen presenting cells to manufacture T cells expressing CD19-specific chimeric antigen receptor. Blood 24: abstract #311.
32. Kenderian S. Ruella M. Gill S. Kalos M. (2014) Chimeric antigen receptor T-cell therapy to target hematologic malignancies. Cancer Res 74: 6383–6389.
33. Kochenderfer J. Rosenberg S. (2013) Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol 10: 267–276.
34. Lazarus H. Advani A. (2012) When, how, and what cell source for hematopoietic cell transplantation in first complete remission adult acute lymphoblastic leukemia? Hematology Am Soc Hematol Educ Program 2012: 382–388.
35. Lee D. Gardner R. Porter D. Louis C. Ahmed N. Jensen M. et al. (2014 a) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124: 188–195.
36. Lee D. Kochenderfer J. Stetler-Stevenson M. Cui Y. Delbrook C. Feldman S. et al. (2014 b) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385: 517–528.
37. Leen A. Myers G. Sili U. Huls M. Weiss H. Leung K. et al. (2006) Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 12: 1160–1166.
38. Loh M. Zhang J. Harvey R. Roberts K. Payne-Turner D. Kang H. et al. (2013) Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the children's oncology group target project. Blood 121: 485–488.
39. Mackall C. Merchant M. Fry T. (2014) Immune-based therapies for childhood cancer. Nat Rev Clin Oncol 11: 693–703.
40. Mantripragada K. Reagan J. Quesenberry P. Fast L. (2014) Advances in cellular therapy for the treatment of leukemia. Discov Med 17: 15–24.
41. Maude S. Barrett D. Teachey D. Grupp S. (2014 a) Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J 20: 119–122.
42. Maude S. Frey N. Shaw P. Aplenc R. Barrett D. Bunin N. et al. (2014 b) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371: 1507–1517.
43. Maus M. Grupp S. Porter D. June C. (2014) Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 123: 2625–2635.
44. Micklethwaite K. Savoldo B. Hanley P. Leen A. Demmler-Harrison G. Cooper L. et al. (2010) Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood 115: 2695–2703.
45. Milone M. Fish J. Carpenito C. Carroll R. Binder G. Teachey D. et al. (2009) Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 17: 1453–1464.
46. Moorman A. Schwab C. Ensor H. Russell L. Morrison H. Jones L. et al. (2012) IGH@ translocations, CRLF 2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia. J Clin Oncol 30: 3100–3108.
47. Nguyen K. Devidas M. Cheng S. La M. Raetz E. Carroll W. et al. (2008) Factors influencing survival after relapse from acute lymphoblastic leukemia: a children's oncology group study. Leukemia 22: 2142–2150.
48. Park J. Sauter C. Brentjens R. (2011) Cellular therapies in acute lymphoblastic leukemia. Hematol Oncol Clin North Am 25: 1281–1301.
49. Porter D. Kalos M. Zheng Z. Levine B. June C. (2011) Chimeric antigen receptor therapy for B-cell malignancies. J Cancer 2: 331–332.
50. Pui C. Robison L. Look A. (2008) Acute lymphoblastic leukaemia. Lancet 371: 1030–1043.
51. Ramos C. Savoldo B. Dotti G. (2014) CD19-CAR trials. Cancer J 20: 112–118.
52. Restifo N. Dudley M. Rosenberg S. (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12: 269–281.
53. Sadelain M. Brentjens R. Riviere I. (2013) The basic principles of chimeric antigen receptor design. Cancer Discov 3: 388–398.
54. Schultz K. Pullen D. Sather H. Shuster J. Devidas M. Borowitz M. et al. (2007) Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood 109: 926–935.
55. Shah N. Nicoll J. Nagar B. Gorre M. Paquette R. Kuriyan J. et al. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2: 117–125.
56. Singh H. Figliola M. Dawson M. Olivares S. Zhang L. Yang G. et al. (2013) Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using sleeping beauty system and artificial antigen presenting cells. PloS ONE 8: e64138.
57. Teachey D. Rheingold S. Maude S. Zugmaier G. Barrett D. Seif A. et al. (2013) Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 121: 5154–5157.
58. Teitell M. Pandolfi P. (2009) Molecular genetics of acute lymphoblastic leukemia. Annu Rev Pathol 4: 175–198.
59. Topp M. Gokbuget N. Stein A. Zugmaier G. O'Brien S. Bargou R. et al. (2015) Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 16: 57–66.
60. Topp M. Gokbuget N. Zugmaier G. Klappers P. Stelljes M. Neumann S. et al. (2014) Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 32: 4134–4140.
61. Topp M. Kufer P. Gokbuget N. Goebeler M. Klinger M. Neumann S. et al. (2011) Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 29: 2493–2498.
62. Turtle C. Sommermeyer D. Berger C. Hudecek M. Shank D. Steevens N. et al. (2014) Therapy of B cell malignancies with CD19-specific chimeric antigen receptor-modified T cells of defined subset composition. Blood 124: abstract #2384.
63. Xu Y. Zhang M. Ramos C. Durett A. Liu E. Dakhova O. et al. (2014) Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood 123: 3750–3759.